References

1. Critchley J, Liu J, Zhao D, Wei W, Capewell S., Explaining the increase in coronary heart disease mortality in Beijing between 1984 and 1999, Circulation, 2004;110:1236-44.

2. Cai L, Zhang L, Liu A et al. Prevalence, awareness, treatment and control of dyslipidemia among adults in Beijing, China. J Atheroscler Thromb 2011 [Epub ahead of print].

3. Moran A, Gu D, Zhao D et al. Future cardiovascular disease in China: Markov model and risk factor scenario projections from the coronary heart disease policy model-china. Circ Cardiovasc Qual Outcomes 2010;3:243-52.

4. The Task Force on the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS); Reiner Z, Catapano A, de Backer G et al. ESC/EAS guidelines for the management of dyslipidaemias. European Heart Journal 2011; 32:1769-818.

5. Banegas JR, Lopez-Garcia E. Dallongeville J et al. Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe. Eur Heart J 2011; 32:2143-52.

6. Appel LJ, Clark JM, Yeh H-C et al. Comparative effectiveness of weight-loss interventions in clinical practice. NEJM 2011;365:1959-68.

7. The AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. New Engl J Med 2011;[Epub ahead of print].

8. Giugliano RP. Niacin at 56 years of age – time for an early retirement? [editorial]. NEJM 2011; [Epub ahead of print].

9. Chapman MJ, Ginsberg HN, Amarenco P et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 2011;32:1345-61.

10. The Coronary Drug Project Group. Clofibrate and niacin in coronary heart disease. JAMA 1975; 231:360-81.

11. Canner PL, Berge KG, Wenger NK et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8:1245-55.

12. Chapman MJ, Redfern JS, McGovern ME, Giral P. Niacin and fibrates in atherogenic dyslipidemia: Pharmacotherapy to reduce cardiovascular risk. Pharmacol Ther 2010;126:314–45.

13. Wu BJ, Yan L, Charlton F, Witting P, Barter PJ, Rye KA. Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids. Arterioscler Thromb Vasc Biol 2010;30:968-75.

14. Wu BJ, Chen K, Barter PJ, Rye KA. Niacin inhibits vascular inflammation via the induction of heme oxygenase-1. Circulation 2011; [Epub ahead of print].

15. Li C, Hossieny P, Wu BJ, Qawasmeh A, Beck K, Stocker R. Pharmacologic induction of heme oxygenase-1. Antioxid Redox Signal 2007;9:2227-39.

16. Otterbein LE, Soares MP, Yamashita K, Bach FH. Heme oxygenase-1: Unleashing the protective properties of heme. Trends Immunol 2003;24:449-55.

17. Stocker R. Antioxidant activities of bile pigments. Antioxid. Redox Signal 2004;6:841-9.

18. Ryter SW, Alam J, Choi AM. Heme oxygenase-1/carbon monoxide: From basic science to therapeutic applications. Physiol Rev 2006;86:583-650.

19. Wu BJ, Midwinter RG, Cassano C et al. Heme oxygenase-1 increases endothelial progenitor cells. Arterioscler Thromb Vasc Biol 2009;29:1537-42.

20. Nicholls SJ, Brewer B, Kastelein JJP et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol. JAMA 2011;306:2099-109.

21. Fayad ZA, Mani V, Woodward M et al. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised trial. Lancet 2011;378:1547-59.

22. Stein EA, Stroes ES, Steiner G et al. Safety and tolerability of dalcetrapib. Am J Cardiol 2009;104:82-91.

23. Cannon CP, Shah S, Dansky HM et al. The DEFINE Investigators. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010;363:2406-15.

24. The Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009;302:1993-2000.

25. Nicholls SJ, Ballantyne CM, Barter PJ et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med 20111; [Epub ahead of print].

26. Heart Protection Study Collaborative Group. Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20 536 high-risk individuals: a randomised controlled trial. Lancet 2011. [Epub ahead of print].